Lilly Gemzar review
Executive Summary
Date for FDA Oncologic Drugs Advisory Committee review of Lilly's Gemzar for advanced ovarian cancer has been changed to March 13. The meeting had been originally scheduled for two days later (1"The Pink Sheet" Jan. 9, 2006, In Brief). The committee is also set to discuss preclinical requirements and Phase I trial design for oncologic products. Meeting date for the committee's Pediatric Oncologic Subcommittee's discussion of Phase IV commitments for Novartis's Exjade (deferasirox) and other topics is still set for March 14. [Editor's note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...